FDA Decision on Replimune (NASDAQ:REPL) Prompts $763 Million in Melanoma Stock Shifts

FDA Decision on Replimune (NASDAQ:REPL) Prompts $763 Million in Melanoma Stock Shifts

A positive FDA decision triggered the movement of nearly $763 million between two melanoma stocks on Friday. Replimune Group saw an increase of around $486 million, while Iovance Biotherapeutics lost approximately $277 million. These figures are based on the most recent common-share counts reported by the companies.

Latest

Southwest Airlines (NYSE:LUV) Maintains Usual Boarding Process as Revenue Pressure Grows, Elevating Performance Risks

Southwest Airlines (NYSE:LUV) Maintains Usual Boarding Process as Revenue Pressure Grows, Elevating Performance Risks

Southwest has not shifted passenger boarding times to an earlier slot. Beginning August 1, select flight attendants on some routes will report five minutes earlier. Passengers will continue to board 30 to 45 minutes prior to departure, with no modifications to the schedule. Multiple travel outlets had conflated these unrelated adjustments.